BioIVT expands European presence with Fidelis Research acquisition
BioIVT has bought European clinical biospecimen collection network Fidelis Research continuing its growth through its acquisition strategy.
Sofia, Bulgaria-headquartered Fidelis Research operates an 85-site collection network of sample collection locations across Southeastern Europe.
In addition to sample collection, the firm also provides cell isolation capabilities and provides custom contract research services for pharmaceutical companies and clinical research organizations (CROs).
BioIVT CEO Richard Haigh cited geographic expansion as the primary motivation for the deal.
“Through Fidelis Research, we deepen our presence in Europe and can provide our clients with a broad array of fresh, clinically collected, disease-state tissues and biofluids, and expanded cell products globally.”
He added, “this transaction further increases the scale and depth of BioIVT's global operations by adding new clinical collection sites, which are predominantly hospital based, focused on oncology, heme-oncology, and autoimmune cases.
“We now have an exemplary global footprint for the collection and provision of high-quality, fully annotated, disease-state biospecimens in Europe, Asia, and the US."
The takeover – financial terms of which were not disclosed – is the third BioIVT has completed in the past few months. In May it bought Cypex, a manufacturer of recombinant xenobiotic metabolizing enzymes, based in Dundee, Scotland.
More recently it acquired ADME-Tox and drug metabolism and pharmacokinetics (DMPK) testing services company XenoTech from Japan’s Sekisui Chemical.
CRL deal
In other news, BioIVT will sell Charles River Laboratories’ range of products supporting vaccine manufacturing and virus research through its digital portal in new agreement.
The deal – with CRL’s avian vaccine services division – is designed to provide developers with quick and easy access to high-quality specific-pathogen-free (SPF) eggs and related laboratory products such as virus antigens and antisera and cells.
Cathie Miller, senior director of product marketing at BioIVT said, “we added advanced biospecimen search and e-commerce capabilities to the BioIVT website about a year ago and the resulting Digital Portal has proven to be a great hit with our customers.
“The addition of the CRL Avian products will enable vaccine focused researchers to quickly access these products."
DepositPhotos/iqoncept